1. Assessing Symptom Burden in Bladder Cancer: An Overview of Bladder Cancer Specific Health-Related Quality of Life Instruments
- Author
-
Erika L. Wood, Bernard J. Danna, Jay B. Shah, and Michael J. Metcalfe
- Subjects
Research Report ,psychometrics ,medicine.medical_specialty ,Psychometrics ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Context (language use) ,Disease ,patient outcome assessment ,urinarydiversion/psychology ,Cystectomy ,03 medical and health sciences ,0302 clinical medicine ,cystectomy ,Quality of life ,medicine ,Stage (cooking) ,Health related quality of life ,Bladder cancer ,business.industry ,Urinary bladder neoplasms/surgery ,medicine.disease ,health surveys ,postoperative complications/psychology ,humanities ,Oncology ,quality of life ,030220 oncology & carcinogenesis ,Physical therapy ,treatment outcome ,business ,cystectomy/psychology - Abstract
Background: A key component to monitoring and investigating patient QOL is through patient reported health related quality of life (HRQOL) outcome measures. Many instruments have been used to assess HRQOL in bladder cancer and each instrument varies in its development, validation, the context of its usage in the literature and its applicability to certain disease states. Objective: In this review, we sought to summarize how clinicians and researchers should most appropriately utilize the available HRQOL instruments for bladder cancer. Methods: We performed a comprehensive literature search of each instrument used in bladder cancer, paying particular attention to the outcomes assessed. We used these outcomes to group the available instruments into categories best reflecting their optimal usage by stage of disease. Results: We found 5 instruments specific to bladder cancer, of which 3 are validated. Only one of the instruments (the EORTC-QLQ-NMIBC24) was involved in a randomized, prospective validation study. The most heavily used instruments are the EORTC-QLQ-BLM30 for muscle-invasive disease and the FACT-Bl which is used across all disease states. Of the 5 available instruments, 4 are automatically administered with general instruments, while the BCI lacks modularity, and requires co-administration with a generalized instrument. Conclusion: There are multiple strong instruments for use in gauging HRQOL in bladder cancer patients. We have divided these instruments into three categories which optimize their usage: instruments for use following NMIBC treatments (EORTC-QLQ-NMIBC24), instruments for use following radical cystectomy (FACT-Bl-Cys and EORTC-QLQ-BLM30) and more inclusive instruments not limited by treatment modality (BCI and FACT-Bl).
- Published
- 2016